Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

Completed · Phase 2

Conditions studied: Lung Cancer, Adenocarcinoma

In brief

This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.

Key facts

Study ID

NCT00430261

Run by

Swedish Medical Center

People needed

20

Starts

2007-01-01

Expected to finish

2010-10-01

Last updated by the study team

2010-10-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Bronchoalveolar carcinoma with disease measurable on CAT scan
• Any lung adenocarcinoma in a never-smoker (less than 100 cigarettes lifetime) with disease measurable on CAT scan
• Stage IIIB or IV

You may not qualify if…

• Uncontrolled hypertension
• Unstable brain metastases
• Pregnant/nursing women
• Uncontrolled thyroid disease

Where it is running

• Swedish Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.